Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial - Thaçi, Diamant; Blauvelt, Andrew; Reich, Kristian; Tsai, Tsen-Fang; Vanaclocha, Francisco; Kingo, Külli; Ziv, Michael; Pinter, Andreas; Hugot, Sophie; You, Ruquan; Milutinovic, Marina (Journal of the American Academy of Dermatology, 2015)
Keywords: 90% or more improvement in baseline Psoriasis Area and Severity Index; Adult; Analysis of Variance; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; clear or almost clear skin; clinical trial; Dermatology; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; head to head; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Middle Aged; plaque psoriasis; Psoriasis - diagnosis; Psoriasis - drug therapy; Reference Values; Risk Assessment; secukinumab; Severity of Illness Index; superiority; Treatment Outcome; ustekinumab; Ustekinumab - administration & dosage; Ustekinumab - adverse effects; clinical trial; DLQI; PASI 90; IGA; PASI; IL; superiority; AE; IGA mod 2011; MedDRA; secukinumab; PASI 75; clear or almost clear skin; TNF; head to head; PASI 100; ustekinumab; SAE; plaque psoriasis; HRQoL; 90% or more improvement in baseline Psoriasis Area and Severity Index; investigator global assessment 2011 modified version; Psoriasis Area and Severity Index; Medical Dictionary for Regulatory Activities; serious adverse event; 75% or more improvement from baseline Psoriasis Area and Severity Index score; interleukin; 100% improvement from baseline Psoriasis Area and Severity Index score; adverse event; health-related quality of life; 90% or more improvement from baseline Psoriasis Area and Severity Index score; investigator global assessment; tumor necrosis factor; Dermatology Life Quality Index